Viruses

Health Secretary makes statement on Covid-19

Retrieved on: 
Tuesday, June 30, 2020
Viruses, Coronaviridae, Animal virology, British MPs, Coronavirus, Jon Ashworth, Matt Hancock

Health Secretary, Matt Hancock updated the House on local action to tackle coronavirus.

Key Points: 
  • Health Secretary, Matt Hancock updated the House on local action to tackle coronavirus.
  • Health Secretary, Matt Hancock told the House that the coronavirus isnow in decline at a national level with the number of positive new cases below a thousand a day, and the number of recorded deaths yesterday was 25.
  • Shadow Health Secretary, Jonathan Ashworth responded to the statement.
  • He asked the Health Secretary: Doesnt he agree that if we are as a nation to ease from lockdown smoothly, then those areas that do see flare ups will need greater response?

Clinical Data of Avifavir to Become Available to International Partners

Retrieved on: 
Monday, June 29, 2020
Health, Viruses, Coronaviridae, Ebola, Animal virology, Favipiravir, Hydroxyarenes, Pyrazines, Coronavirus, Chromis, Clinical trial

Avifavir (INN: favipiravir) was registered as one of the first global drugs, and the first in the Russian Federation, to treat the coronavirus infection.

Key Points: 
  • Avifavir (INN: favipiravir) was registered as one of the first global drugs, and the first in the Russian Federation, to treat the coronavirus infection.
  • Avifavir has proven to be effective in clinical trials, and we are committed to helping other countries obtain an additional effective treatment for people infected with coronavirus.
  • Please note that all the distribution rights for Avifavir belong to ChemRar Group of Companies and OOO CHROMIS.
  • No other entity or individual is authorized by ChemRar to distribute Avifavir or conduct ANY negotiations on behalf of ChemRar Group of Companies or OOO CHROMIS.

Clinical Data of Avifavir to Become Available to International Partners

Retrieved on: 
Monday, June 29, 2020
Health, Viruses, Coronaviridae, Ebola, Animal virology, Favipiravir, Hydroxyarenes, Pyrazines, Coronavirus, Chromis, Clinical trial

Avifavir (INN: favipiravir) was registered as one of the first global drugs, and the first in the Russian Federation, to treat the coronavirus infection.

Key Points: 
  • Avifavir (INN: favipiravir) was registered as one of the first global drugs, and the first in the Russian Federation, to treat the coronavirus infection.
  • Avifavir has proven to be effective in clinical trials, and we are committed to helping other countries obtain an additional effective treatment for people infected with coronavirus.
  • Please note that all the distribution rights for Avifavir belong to ChemRar Group of Companies and OOO CHROMIS.
  • No other entity or individual is authorized by ChemRar to distribute Avifavir or conduct ANY negotiations on behalf of ChemRar Group of Companies or OOO CHROMIS.

Cell Publication Elucidates How SARS-CoV-2 Dramatically Rewires Important Cell Programming; Identifies Existing Therapeutics That May Fight COVID-19

Retrieved on: 
Sunday, June 28, 2020
Viruses, Severe acute respiratory syndrome-related coronavirus, Kinase, Vaccinia

The scientists collaborated with Zoic Labs to overlay this new phosphorylation information onto the interactive version of the previously published protein-protein interaction map .

Key Points: 
  • The scientists collaborated with Zoic Labs to overlay this new phosphorylation information onto the interactive version of the previously published protein-protein interaction map .
  • The team determined that 40 of the 332 human proteins that interact with SARS-CoV-2 were significantly differentially phosphorylated in cells infected with SARS-CoV-2.
  • Because kinases possess certain structural features, they are very druggable targets with more than 500 compounds commercially available or in development.
  • Conversely, other viruses including vaccinia, Ebola and Marburg take over the host cell cytoskeleton to promote egress and rapid cell-to-cell spread.

World Asian Medical Journal REWIND: Joanne Liu and Patrick Soon-Shiong

Retrieved on: 
Friday, June 26, 2020
Viruses, Veterinary medicine, Animal virology, Coronaviridae, Coronavirus, Englewood Cliffs, New Jersey, Middle East respiratory syndrome-related coronavirus

ENGLEWOOD CLIFFS, N.J., June 26, 2020 /PRNewswire/ -- The World Asian Medical Journal, otherwise known as WAMJ, is published to present multidisciplinary perspectives on healthcare and related issues.

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., June 26, 2020 /PRNewswire/ -- The World Asian Medical Journal, otherwise known as WAMJ, is published to present multidisciplinary perspectives on healthcare and related issues.
  • The following interviews ran in the 2019 and 2020 editions of WAMJ as the 'Inspirational Healthcare Leader' features.
  • While the conversations may be from a few editions back, these glimpses of healthcare heroes still resonate as the world continues the fight against the novel coronavirus.
  • W Medical Strategy Group is a cross-border healthcare consulting firm that uses deep industry expertise to help companies achieve optimal business results.

36.8 Million Americans To Hit the Road for Fourth of July

Retrieved on: 
Wednesday, June 24, 2020
Viruses, Animal diseases, Health in Saudi Arabia, In Saudi Arabia, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Zoonoses, Tourism, Veterinary medicine

Arrivalist recently revealed that Memorial Day road trip activity returned to pre-COVID levels.

Key Points: 
  • Arrivalist recently revealed that Memorial Day road trip activity returned to pre-COVID levels.
  • Despite widespread social unrest and ongoing health threats from the novel coronavirus, the Daily Travel Index, a free resource posted online , continues to rise.
  • Arrivalist predicts the Daily Travel Index will cross 100% for the first time over the Fourth of July weekend, meaning that twice as many travelers will hit the road compared to an average day in February.
  • Arrivalist launched the Daily Travel Index on April 1, providing free access to the travel industry and the public.

Biocare Medical MACH4 Universal Polymer Utilized by CDC for Immunohistochemical Detection of SARS-CoV-2 in COVID-19 Caused Respiratory Infections

Retrieved on: 
Wednesday, June 24, 2020
Viruses, Zoonoses, Articles, In Saudi Arabia, Middle East respiratory syndrome, Coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Pandemic, CoV

The ongoing pandemic of the novel coronavirus disease (COVID-19), as caused by the SARS-CoV-2 virus, has created an urgent need for new research into diagnostic testing and treatments.

Key Points: 
  • The ongoing pandemic of the novel coronavirus disease (COVID-19), as caused by the SARS-CoV-2 virus, has created an urgent need for new research into diagnostic testing and treatments.
  • The recent CDC study of autopsied lung tissue from fatal cases has utilized Biocare's MACH4 Universal AP Polymer Detection along with our unique antigen retrieval buffers in order to obtain key immunohistological findings regarding the virus's localization in the lungs.
  • Biocare Medical is excited to announce the use of our novel detection system MACH4 Universal AP Detection system to aid the CDC in the pathologic evaluation and cellular localization within tissues, which will be crucial in the development of therapeutic and preventative countermeasures to this global pandemic.
  • To Read the Full CDC Early Release Visit the Link Below:
    Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States

Novavax to Participate in H.C. Wainwright Fireside Chat Series

Retrieved on: 
Wednesday, June 24, 2020
Vaccines, Novavax, Viruses, Adjuvants, Health, Vaccine, Medicine, Severe acute respiratory syndrome-related coronavirus, H5N1 clinical trials, Ebola vaccine

Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.

Key Points: 
  • Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
  • Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
  • Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

Retrieved on: 
Wednesday, June 24, 2020
Viruses, Animal virology, Coronaviridae, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Orthocoronavirinae

The patent application, entitled MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION, describes a platform to generate multi-valent molecular constructs (decoy receptors) that have the potential to prevent coronaviruses including the SARS-CoV-2 virus (the virus that causes Coronavirus Disease 2019 (COVID-19)) from entering (infecting) healthy host cells.

Key Points: 
  • The patent application, entitled MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION, describes a platform to generate multi-valent molecular constructs (decoy receptors) that have the potential to prevent coronaviruses including the SARS-CoV-2 virus (the virus that causes Coronavirus Disease 2019 (COVID-19)) from entering (infecting) healthy host cells.
  • Multi-valent constructs described in the patent application are believed to have both therapeutic and diagnostic potential, the latter in the context of determining whether a patient has developed coronavirus-specific antibodies.
  • The Company cautions that these novel therapeutics are still under early-stage research and development and is not making any express or implied claims as to their success in treatment or commercial viability.
  • The patent application seeks protection for, among others, the design of new therapeutics and diagnostics and methods for their use.

Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual

Retrieved on: 
Wednesday, June 24, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, AIDS, Health, Pharmaceutical, General Health, Science, Articles, Viruses, Health, HIV/AIDS, Pandemics, Reverse-transcriptase inhibitor, HIV, Prevention of HIV/AIDS, Management of HIV/AIDS, Islatravir (MK-8591), Merck

Select abstracts in the AIDS 2020 program include:

Key Points: 
  • Select abstracts in the AIDS 2020 program include:
    Islatravir Safety Analysis Through Week 48 From A Phase 2 Trial in Treatment Nave Adults With HIV-1 Infection.
  • Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Nave Participants from Phase 3 Clinical Trials.
  • For more information, including details around the virtual programming, please visit the AIDS 2020 website .
  • Our focus is on pursuing research that addresses unmet medical needs and helps people living with HIV and their communities.